Table 3 Characteristics of participants achieving and not achieving treatment goals among LLD and antihypertensive drug users

Sex, n (%)

 Women

29

(21.3)

262

(26.4)

123

(32.5)

132

(34.6)

Age, mean (sd)

69.7

(9.5)

69.4

(9.8)

68.0

(9.7)

71.6

(9.6)

Smoking, n (%)

 Daily smoking

15

(11.0)

114

(11.5)

52

(13.7)

29

(7.5)

 Smoked previously

79

(58.1)

617

(62.3)

218

(57.5)

236

(61.8)

Self-reported health, n (%)

 Excellent/good

56

(41.2)

478

(48.2)

157

(41.4)

161

(42.1)

 Neither good nor bad

68

(50.0)

403

(40.7)

175

(46.2)

177

(46.3)

 Bad/very bad

9

(6.6)

99

(10.0)

44

(11.6)

40

(10.4)

Comorbidities*, n (%)

 Heart failure

20

(14.7)

176

(17.8)

72

(19.0)

65

(17.0)

 Atrial fibrillation

23

(16.9)

181

(18.3)

84

(22.1)

76

(19.9)

 Stroke

12

(8.8)

90

(9.1)

45

(11.9)

46

(12.0)

 Diabetes

28

(20.6)

147

(14.8)

72

(19.0)

74

(19.4)

 Renal disease

7

(5.2)

71

(7.1)

25

(6.6)

40

(10.5)

 Cancer

18

(13.2)

124

(12.5)

44

(11.6)

60

(15.8)

 Medications, mean number of products (sd)

5.3

(2.9)

4.4

(2.8)

5.0

(2.9)

5.0

(2.9)

Clinical measurements, mean (sd)

 Systolic blood pressure, mmHg

133

(18.5)

136

(21.0)

123

(11.7)

155

(15.4)

 Diastolic blood pressure, mmHg

73

(9.2)

74

(9.8)

71

(8.5)

79

(9.6)

 Total cholesterol, mmol/l^†

3.3

(0.6)

4.5

(0.9)

4.4

(1.0)

4.6

(1.1)

 LDL-cholesterol, mmol/l^†

1.5

(0.2)

2.7

(0.8)

2.7

(0.9)

2.8

(1.0)

 HDL-cholesterol, mmol/l^†

1.5

(0.6)

1.4

(0.4)

1.4

(0.4)

1.4

(0.4)

 Triglycerides, mmol/l^‡

1.5

(1.6)

1.6

(0.9)

1.7

(0.9)

1.7

(1.1)

 HbA1c, %

6.3

(1.0)

6.1

(0.9)

6.1

(1.0)

6.1

(1.0)

 Glucose, mmol/l^§

6.5

(2.7)

6.0

(2.1)

6.2

(2.3)

6.2

(2.2)

 BMI, kg/m²

28.4

(4.6)

28.4

(4.3)

29.2

(4.6)

28.9

(4.4)